Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 3, 2014, Pages 586-595

  Mallajosyula, Jyothi K ^a   Hiatt, Ernie ^b   Hume, Steve ^b   Johnson, Ashley ^b   Jeevan, Trushar ^c   Chikwamba, Rachel ^d   Pogue, Gregory P ^b,e   Bratcher, Barry ^b   Haydon, Hugh ^b   Webby, Richard J ^c   McCormick, Alison A ^a  

^a TOURO UNIVERSITY CALIFORNIA   (United States)

^b Kentucky BioProcessing   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d Future production Chemicals Cluster   (South Africa)

^e UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Dose sparing; H1N1; Ha subunit protein; Influenza; Nanoparticle; Plant made pharmaceuticals; Vaccination

Indexed keywords

ALUMINUM HYDROXIDE; HEMAGGLUTININ; INFLUENZA VACCINE; DRUG CARRIER; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INFLUENZA VIRUS HEMAGGLUTININ; RECOMBINANT VACCINE; SUBUNIT VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONJUGATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; HEMAGGLUTINATION INHIBITION; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA VACCINATION; MOUSE; NONHUMAN; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SINGLE DRUG DOSE; TOBACCO MOSAIC VIRUS; VIRUS IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; DISEASE MODEL; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE INFECTIONS; PROCEDURES; SURVIVAL ANALYSIS; TOBAMOVIRUS; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; DRUG CARRIERS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS; INFLUENZA VACCINES; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; TOBAMOVIRUS; VACCINATION; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84898409765     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27567     Document Type: Article

References (52)

1. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36-44; PMID:22032844; http://dx.doi.org/10.1016/ S1473-3099(11)70295-X
2. Girard MP, Katz JM, Pervikov Y, Hombach J, Tam JS. Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17-18 February 2011. Vaccine 2011; 29:7579-86; PMID:21856358; http://dx.doi.org/10.1016/j.vaccine.2011.08.031
3. Hoa LK, Hiep LV, Be LV. Development of pandemic influenza vaccine production capacity in Viet Nam. Vaccine 2011; 29(Suppl 1):A34-6; PMID:21684426; http://dx.doi.org/10.1016/j.vaccine.2011.04.118
4. Stephenson I, Gust I, Pervikov Y, Kieny MP. Development of vaccines against influenza H5. Lancet Infect Dis 2006; 6:458-60; PMID:16870521; http://dx.doi.org/10.1016/S1473-3099(06)70528-X
5. Dormitzer PR, Suphaphiphat P, Gibson DG, Wentworth DE, Stockwell TB, Algire MA, Alperovich N, Barro M, Brown DM, Craig S, et al. Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med 2013; 5:85ra68; PMID:23677594; http://dx.doi.org/10.1126/scitranslmed.3006368
6. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, Holmes S. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010; 51:997-1004; PMID:20868284; http://dx.doi.org/10.1086/656578
7. Extance A. Cell-based flu vaccines ready for US prime time. Nat Rev Drug Discov 2011; 10:246; PMID:21455223; http://dx.doi.org/10.1038/nrd3414
8. Jung EJ, Lee KH, Seong BL. Reverse genetic platform for inactivated and live-attenuated influenza vaccine. Exp Mol Med 2010; 42:116-21; PMID:20054235; http://dx.doi.org/10.3858/emm.2010.42.2.013
9. Tseng YF, Hu AY, Huang ML, Yeh WZ, Weng TC, Chen YS, Chong P, Lee MS. Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness. PLoS One 2011; 6:e24057; PMID:22022351; http://dx.doi.org/10.1371/journal.pone.0024057
10. Ng SK. Current cell-based influenza vaccine production technology as pandemic contingency. Hum Vaccin Immunother 2012; 8:267-71; PMID:22426381; http://dx.doi.org/10.4161/hv.18336
11. Boslego J. Influenza Vaccine Strategies for Broad Global Access. PATH Publications, 2007.
12. Collin N, de Radiguès X; World Health Organization H1N1 Vaccine Task Force. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza. Vaccine 2009; 27:5184-6; PMID:19563891; http://dx.doi.org/10.1016/j. vaccine.2009.06.034
13. Pandey A, Singh N, Sambhara S, Mittal SK. Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum Vaccin 2010; 6:178-88; PMID:19875936; http://dx.doi.org/10.4161/hv.6.2.9899
14. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368:1888-97; PMID:23577628; http://dx.doi.org/10.1056/NEJMoa1304459
15. Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011; 29:7733-9; PMID:21835220; http://dx.doi.org/10.1016/j.vaccine.2011.07.128
16. Cox MM, Hashimoto Y. A fast track influenza virus vaccine produced in insect cells. J Invertebr Pathol 2011; 107(Suppl):S31-41; PMID:21784229; http://dx.doi.org/10.1016/j.jip.2011.05.003
17. Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, Manischewitz J, King LR, Ross TM, Golding H. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets. J Virol 2011; 85:1246-56; PMID:21084473; http://dx.doi.org/10.1128/JVI.02107-10
18. Shoji Y, Farrance CE, Bautista J, Bi H, Musiychuk K, Horsey A, Park H, Jaje J, Green BJ, Shamloul M, et al. A plant-based system for rapid production of influenza vaccine antigens. Influenza Other Respir Viruses 2012; 6:204-10; PMID:21974811; http://dx.doi.org/10.1111/j.1750-2659.2011.00295.x
19. Mortimer E, Maclean JMJ, Mbewana S, Buys A, Williamson ALA, Hitzeroth III, Rybicki EPE. Setting up a platform for plant-based influenza virus vaccine production in South Africa. BMC Biotechnol 2012; 12:14; PMID:22536810; http://dx.doi.org/10.1186/1472-6750-12-14
20. D'Aoust MA, Lavoie PO, Couture MM, Trépanier S, Guay JM, Dargis M, Mongrand S, Landry N, Ward BJ, Vézina LP. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J 2008; 6:930-40; PMID:19076615; http://dx.doi.org/10.1111/j.1467-7652.2008.00384. x
21. Tretyakova I, Pearce MB, Florese R, Tumpey TM, Pushko P. Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses. Virology 2013; 442:67-73; PMID:23618102; http://dx.doi.org/10.1016/j.virol.2013.03.027
22. Landry N, Ward BJ, Trépanier S, Montomoli E, Dargis M, Lapini G, Vézina LP. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 2010; 5:e15559; PMID:21203523; http://dx.doi.org/10.1371/journal.pone.0015559
23. Chichester JA, Jones RM, Green BJ, Stow M, Miao F, Moonsammy G, Streatfield SJ, Yusibov V. Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthy adults. Viruses 2012; 4:3227-44; PMID:23202523; http://dx.doi.org/10.3390/v4113227
24. McCormick AA, Corbo TA, Wykoff-Clary S, Nguyen LV, Smith ML, Palmer KE, Pogue GP. TMV-peptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models. Vaccine 2006; 24:6414-23; PMID:16860441; http://dx.doi.org/10.1016/j.vaccine.2006.06.003
25. McCormick AA, Corbo TA, Wykoff-Clary S, Palmer KE, Pogue GP. Chemical conjugate TMV-peptide bivalent fusion vaccines improve cellular immunity and tumor protection. Bioconjug Chem 2006; 17:1330-8; PMID:16984144; http://dx.doi.org/10.1021/bc060124m
26. McCormick AA, Palmer KE. Genetically engineered Tobacco mosaic virus as nanoparticle vaccines. Expert Rev Vaccines 2008; 7:33-41; PMID:18251692; http://dx.doi.org/10.1586/14760584.7.1.33
27. Smith ML, Fitzmaurice WP, Turpen TH, Palmer KE. Display of peptides on the surface of tobacco mosaic virus particles. Curr Top Microbiol Immunol 2009; 332:13-31; PMID:19401819; http://dx.doi.org/10.1007/978-3-540-70868-1-2
28. Smith ML, Lindbo JA, Dillard-Telm S, Brosio PM, Lasnik AB, McCormick AA, Nguyen LV, Palmer KE. Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. Virology 2006; 348:475-88; PMID:16466765; http://dx.doi.org/10.1016/j.virol.2005.12.039
29. Gleba Y, Klimyuk V, Marillonnet S. Magnifection - a new platform for expressing recombinant vaccines in plants. Vaccine 2005; 23:2042-8; PMID:15755568; http://dx.doi.org/10.1016/j.vaccine.2005.01.006
30. Gleba Y, Klimyuk V, Marillonnet S. Viral vectors for the expression of proteins in plants. Curr Opin Biotechnol 2007; 18:134-41; PMID:17368018; http://dx.doi.org/10.1016/j.copbio.2007.03.002
31. Gleba YY, Tusé D, Giritch A. Plant viral vectors for delivery by agrobacterium. Curr Top Microbiol Immunol 2014; 375:155-92; PMID:23949286
32. Palmer KE, Benko A, Doucette SA, Cameron TI, Foster T, Hanley KM, McCormick AA, McCulloch M, Pogue GP, Smith ML, et al. Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes. Vaccine 2006; 24:5516-25; PMID:16725236; http://dx.doi.org/10.1016/j.vaccine.2006.04.058
33. Mason HS, Lam DM, Arntzen CJ. Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci U S A 1992; 89:11745-9; PMID:1465391; http://dx.doi.org/10.1073/pnas.89.24.11745
34. Mason HS, Haq TA, Clements JD, Arntzen CJ. Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine 1998; 16:1336-43; PMID:9682399; http://dx.doi.org/10.1016/S0264-410X(98)80020-0
35. Yusibov V, Modelska A, Steplewski K, Agadjanyan M, Weiner D, Hooper DC, Koprowski H. Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Proc Natl Acad Sci U S A 1997; 94:5784-8; PMID:9159151; http://dx.doi.org/10.1073/pnas.94.11.5784
36. Yusibov V, Shivprasad S, Turpen TH, Dawson W, Koprowski H. Plant viral vectors based on tobamoviruses. Curr Top Microbiol Immunol 1999; 240:81-94; PMID:10394716
37. Pogue GP, Lindbo JA, Garger SJ, Fitzmaurice WP. Making an ally from an enemy: plant virology and the new agriculture. Annu Rev Phytopathol 2002; 40:45-74; PMID:12147754; http://dx.doi.org/10.1146/annurev.phyto.40.021102. 150133
38. Rybicki EP. Plant-made vaccines for humans and animals. Plant Biotechnol J 2010; 8:620-37; PMID:20233333; http://dx.doi.org/10.1111/j.1467-7652.2010. 00507.x
39. Paul M, van Dolleweerd C, Drake PM, Reljic R, Thangaraj H, Barbi T, Stylianou E, Pepponi I, Both L, Hehle V, et al. Molecular Pharming: future targets and aspirations. Hum Vaccin 2011; 7:375-82; PMID:21368584; http://dx.doi.org/10.4161/hv.7.3.14456
40. Klimyuk V, Pogue G, Herz S, Butler J, Haydon H. Production of Recombinant Antigens and Antibodies in Nicotiana benthamiana Using 'Magnifection' Technology: GMP-Compliant Facilities for Small- and Large-Scale Manufacturing. Curr Top Microbiol Immunol 2014; 375:127-54; PMID:22527176
41. Mett V, Musiychuk K, Bi H, Farrance CE, Horsey A, Ugulava N, Shoji Y, de la Rosa P, Palmer GA, Rabindran S, et al. A plant-produced influenza subunit vaccine protects ferrets against virus challenge. Influenza Other Respir Viruses 2008; 2:33-40; PMID:19453491; http://dx.doi.org/10.1111/j.1750-2659.2008.00037. x
42. Morhard R, Bouri N, Gilles K, Rambhia KJ, Ravi SJ, Sell TK, Watson M. HHS Releases New Strategy for Emergency Medical Countermeasures Enterprise. Biosecur Bioterror 2012; 10:247-54; PMID:22967169
43. Shoji Y, Jones RM, Mett V, Chichester JA, Musiychuk K, Sun X, Tumpey TM, Green BJ, Shamloul M, Norikane J, et al. A plant-produced H1N1 trimeric hemagglutinin protects mice from a lethal influenza virus challenge. Hum Vaccin Immunother 2013; 9:9; PMID:23296194; http://dx.doi.org/10.4161/hv.23234
44. Wei CJ, Xu L, Kong WP, Shi W, Canis K, Stevens J, Yang ZY, Dell A, Haslam SM, Wilson IA, et al. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J Virol 2008; 82:6200-8; PMID:18417563; http://dx.doi.org/10.1128/JVI.00187-08
45. Vanlandschoot P, Beirnaert E, Neirynck S, Saelens X, Jou WM, Fiers W. Molecular and immunological characterization of soluble aggregated A/Victoria/3/75 (H3N2) influenza haemagglutinin expressed in insect cells. Arch Virol 1996; 141:1715-26; PMID:8893793; http://dx.doi.org/10.1007/BF01718294
46. Kemnade JO, Seethammagari M, Collinson-Pautz M, Kaur H, Spencer DM, McCormick AA. Tobacco Mosaic Virus Efficiently Targets DC uptake, Activation and Antigen-specific T Cell Responses in vivo. Vaccine 2013; Submitted.
47. Liu R, Vaishnav RA, Roberts AM, Friedland RP. Humans have antibodies against a plant virus: evidence from tobacco mosaic virus. PLoS One 2013; 8:e60621; PMID:23573274; http://dx.doi.org/10.1371/journal.pone.0060621
48. Hermanson G. Bioconjugate Techniques. Elsevier, 2008.
49. McCormick AA, Kumagai MH, Hanley K, Turpen TH, Hakim I, Grill LK, Tusé D, Levy S, Levy R. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc Natl Acad Sci U S A 1999; 96:703-8; PMID:9892697; http://dx.doi.org/10.1073/pnas.96.2.703
50. Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. Am J Transplant 2011; 11:2250-5; PMID:21957937; http://dx.doi.org/10.1111/j.1600-6143.2011.03793.x
51. Saveyn H, De Baets B, Thas O, Hole P, Smith J, Van der Meeren P. Accurate particle size distribution determination by nanoparticle tracking analysis based on 2-D Brownian dynamics simulation. J Colloid Interface Sci 2010; 352:593-600; PMID:20887997; http://dx.doi.org/10.1016/j.jcis.2010.09.006
52. Pizzi M. Sampling variation of the fifty percent end-point, determined by the Reed-Muench (Behrens) method. Hum Biol 1950; 22:151-90; PMID:14778593